Felzartamab, a recombinant fully human monoclonal antibody against CD38, is currently in a phase 2a trial for patients with IgA nephropathy (IGNAZ; NCT05065970) (Table 1). This evidence concerns the gene CD38 and IgA glomerulonephritis.